Xiao et al., 2024 - Google Patents
Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F] SynVesT‐1Xiao et al., 2024
View PDF- Document ID
- 5021912785165614144
- Author
- Xiao L
- Xiang S
- Chen C
- Zhu H
- Zhou M
- Tang Y
- Feng L
- Hu S
- Publication year
- Publication venue
- Psychiatry and Clinical Neurosciences
External Links
Snippet
Aim Cognitive impairment is a common comorbidity in individuals with temporal lobe epilepsy (TLE), yet the underlying mechanisms remain unknown. This study explored the putative association between in vivo synaptic loss and cognitive outcomes in TLE patients …
- 201000008914 temporal lobe epilepsy 0 title abstract description 106
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease | |
| Erritzoe et al. | Brain serotonin release is reduced in patients with depression: a [11C] Cimbi-36 positron emission tomography study with a d-amphetamine challenge | |
| Wilson et al. | Mitochondrial complex 1, sigma 1, and synaptic vesicle 2A in early drug‐naive Parkinson's disease | |
| Sundal et al. | MRI characteristics and scoring in HDLS due to CSF1R gene mutations | |
| Brabazon et al. | Intranasal insulin treatment of an experimental model of moderate traumatic brain injury | |
| Hu et al. | Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults | |
| Nordanskog et al. | Hippocampal volume in relation to clinical and cognitive outcome after electroconvulsive therapy in depression | |
| Gildengers et al. | Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder | |
| Pettorruso et al. | Striatal presynaptic dopaminergic dysfunction in gambling disorder: A 123I‐FP‐CIT SPECT study | |
| Tang et al. | Spatial learning and memory impairments are associated with increased neuronal activity in 5XFAD mouse as measured by manganese-enhanced magnetic resonance imaging | |
| Vegting et al. | The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies | |
| Sydnor et al. | Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects | |
| Xiao et al. | Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F] SynVesT‐1 | |
| Sihvonen et al. | Right hemispheric structural connectivity and poststroke language recovery | |
| Trigiani et al. | A functional cerebral endothelium is necessary to protect against cognitive decline | |
| Duara et al. | The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium | |
| Tiger et al. | [11C] raclopride positron emission tomography study of dopamine‐D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects | |
| Beglopoulos et al. | Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice | |
| Onos et al. | Assessment of neurovascular uncoupling: APOE status is a key driver of early metabolic and vascular dysfunction | |
| Dai et al. | Expansion of clinical and genetic spectrum of DDX3X neurodevelopmental disorder in 23 Chinese patients | |
| Ponirakis et al. | Corneal nerve loss predicts dementia in patients with mild cognitive impairment | |
| Fatima et al. | Breakthroughs in Alzheimer’s research: a path to a more promising future? | |
| Suchy‐Dicey et al. | Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study | |
| Boecker‐Schlier et al. | Association between pubertal stage at first drink and neural reward processing in early adulthood | |
| Bäckström et al. | PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study |